Literature DB >> 1607607

Inflammatory bowel disease: costs-of-illness.

J W Hay1, A R Hay.   

Abstract

We have evaluated the economic costs to society for the two major types of inflammatory bowel disease, Crohn's disease and ulcerative colitis, using a medical decision algorithm costing methodology augmented by examination of 1988-89 claims data from a major U.S. commercial insurer. The average annual medical cost per patient with Crohn's disease was estimated at $6,561 (1990 U.S. dollars). The total annual medical costs for U.S. Crohn's disease patients in 1990 was estimated at $1.0-1.2 billion. The average annual medical cost per patient with ulcerative colitis was estimated at $1,488. The total annual medical costs for U.S. patients with ulcerative colitis in 1990 was estimated at $0.4-0.6 billion. Adjusting for productivity losses, we estimated the annual economic cost for both diseases at $1.8 billion to $2.6 billion. Analysis of insurance claims data for inflammatory bowel disease patients showed that the distribution of annual medical expenses charged and paid is highly uneven by patient. The top 2% of Crohn's disease patients accounted for 28.9% of total charges and 34.3% of the total amount paid. The top 2% of ulcerative colitis patients accounted for 36.2% of total charges and 39.0% of the total amount paid. We used a multivariate regression model to examine potential cost-effectiveness tradeoffs between different types of medical services in treatment of inflammatory bowel disease.

Entities:  

Mesh:

Year:  1992        PMID: 1607607     DOI: 10.1097/00004836-199206000-00009

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  51 in total

1.  Protagonist: Early surgical intervention in ulcerative colitis.

Authors:  R R Cima; J H Pemberton
Journal:  Gut       Date:  2004-02       Impact factor: 23.059

2.  Health care costs of complex perianal fistula in Crohn's disease.

Authors:  M Chaparro; C Zanotti; P Burgueño; I Vera; F Bermejo; I Marín-Jiménez; C Yela; P López; M D Martín; C Taxonera; B Botella; R Pajares; A Ponferrada; M Calvo; A Algaba; L Pérez; B Casis; J Maté; J Orofino; N Lara; M García-Losa; X Badia; J P Gisbert
Journal:  Dig Dis Sci       Date:  2013-09-13       Impact factor: 3.199

Review 3.  Optimal use and cost-effectiveness of biologic therapies in inflammatory bowel disease.

Authors:  Antonio Di Sabatino; Lucio Liberato; Monia Marchetti; Paolo Biancheri; Gino R Corazza
Journal:  Intern Emerg Med       Date:  2011-10       Impact factor: 3.397

Review 4.  Economic implications of biological therapies for Crohn's disease: review of infliximab.

Authors:  Keith Bodger
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

5.  Costs of inflammatory bowel disease in Germany.

Authors:  Renee Stark; Hans-Helmut König; Reiner Leidl
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

Review 6.  Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution.

Authors:  Annabel Kuek; Brian L Hazleman; Andrew J K Ostör
Journal:  Postgrad Med J       Date:  2007-04       Impact factor: 2.401

Review 7.  Cost of illness of Crohn's disease.

Authors:  Keith Bodger
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

8.  The characterization of a rabbit model of inflammatory bowel disease.

Authors:  D Anthony; F Savage; V Sams; P Boulos
Journal:  Int J Exp Pathol       Date:  1995-06       Impact factor: 1.925

9.  Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults.

Authors:  Michael D Kappelman; Sheryl L Rifas-Shiman; Carol Q Porter; Daniel A Ollendorf; Robert S Sandler; Joseph A Galanko; Jonathan A Finkelstein
Journal:  Gastroenterology       Date:  2008-09-17       Impact factor: 22.682

10.  Demographic and Clinical Predictors of High Healthcare Use in Patients with Inflammatory Bowel Disease.

Authors:  Benjamin Click; Claudia Ramos Rivers; Ioannis E Koutroubakis; Dmitriy Babichenko; Alyce M Anderson; Jana G Hashash; Michael A Dunn; Marc Schwartz; Jason Swoger; Leonard Baidoo; Arthur Barrie; Miguel Regueiro; David G Binion
Journal:  Inflamm Bowel Dis       Date:  2016-06       Impact factor: 5.325

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.